ArticleThe oncologist2022

Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center.

Erik S Knudsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.